偷拍偷窥

News

New surfactant could improve lung treatments for premature babies

Researchers report progress toward an alternative to animal-derived formulation
Anne Frances Johnson
March 24, 2024

Scientists have developed a new lung surfactant that is produced synthetically rather than relying on the use of animal tissues. With further development, the formulation could provide a cheaper and more readily available alternative to Infasurf, a medication used to prevent and treat respiratory distress in premature babies.

Surfactants are substances that decrease surface tension where liquids interface with other liquids, gases or solids. In addition to their use in medicines, they are found in a wide range of products including detergents, cosmetics, motor oils and adhesives.

Scientists at Discover BMB in San Antonio reported a new lung surfactant that is produced synthetically rather than derived using animal tissues. It might eventually provide a cheaper and more accessible alternative to medication currently used to prevent and treat respiratory distress in premature babies.
Scientists at Discover BMB in San Antonio reported a new lung surfactant that is produced synthetically rather than derived using animal tissues. It might eventually provide a cheaper and more accessible alternative to medication currently used to prevent and treat respiratory distress in premature babies.

Suzanne Farver Lukjan, a lecturer in chemistry at Troy University in Alabama, led the work.

“A synthetic surfactant could potentially have a longer shelf life, lower production costs, have less batch variability and pose less risk of an immune response compared to animal-derived lung surfactants,” she said. “We hope our formulation will one day be used in hospitals.”

Lukjan will present the research at , the annual meeting of the 偷拍偷窥 and 偷拍偷窥 Biology, which is being held March 23–26 in San Antonio.

Lung surfactants help premature babies breathe while their lung cells finish developing. In addition to offering a potential alternative to replace Infasurf for babies, researchers say the new synthetic surfactant could be useful for treating adults with lung injuries as a result of diseases such as chronic obstructive pulmonary disorder, miner’s lung or emphysema.

Researchers have previously attempted to develop synthetic lung surfactants, but some have been removed from the market and others have not been able to lower surface tension as well as animal-derived formulations.

In the new work, Lukjan’s team created candidate surfactants from synthetic lipids (fats) and peptides (short chains of amino acids) and then tested their surface-tension-lowering capabilities. They aimed to mimic the composition, lipid phase behavior and biophysical function of Infasurf as closely as possible.

After tweaking a step in the sample preparation process, the researchers found a few formulations that showed particular promise. Although tests demonstrated that the chemical behavior of the synthetic surfactants was quite different from that of Infasurf, the new surfactants were able to mimic the drug’s functionality in terms of lowering surface tension and seem to achieve the optimal range in terms of peptide concentration.

As a next step, Lukjan said, the group plans to continue to refine and test their formulation to further optimize the combination of lipids and peptides. The surfactant would also need to undergo safety testing before it could be used clinically.

This work was partially funded by ONY Biotech Inc., maker of Infasurf.  

Suzanne Lukjan will present this research from 4:30 to 6:30 p.m. CDT on Monday, March 25, in the exhibit hall of the Henry B. Gonz谩lez Convention Center (Poster Board No. 210) (). 

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Anne Frances Johnson

Anne Frances Johnson is founder and lead science writer at based in Chapel Hill, North Carolina. 

Get the latest from ASBMB Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in 偷拍偷窥 & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥� to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Feature

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥� and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
Feature

Using 'nature鈥檚 mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
News

Cracking cancer鈥檚 code through functional connections

July 2, 2025

A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.